QuidelOrtho Corporation

QuidelOrtho Corporation

QDELNYSE / NASDAQHealthcareSmall cap

$8.32-$0.60 (-6.7%)

Last close · Data as of Nov 20, 2026

Market cap
$1.0B
P/E
-0.9x
EV / EBITDA
-7.7x
Revenue
$2.7B
Net margin
-41.5%
ROCE
1.1%

-61.0% over the last year

QuidelOrtho Corporation price, 1Y

Daily closes.

Go deeper

Technical chart: candles, 28 indicators including moving averages, RSI and MACD, drawing tools and five colour themes

Open technical chart
Open technical chartCandles, 28 indicators, drawing tools

Performance

Price return, before dividends, to the 20 Nov 2026 close.

1M
-41.4%
3M
-44.0%
6M
-30.1%
1Y
-61.0%
5Y
-94.5%

52-week range

Day change -$0.60 (-6.7%) from $9 to $8 · Last close Nov 20, 2026

Best weekday to invest, historically

The same weekly amount in QDEL, bought on each weekday since 2021.

News & filings

What QuidelOrtho filed, who traded, and what's next

How to read this

"News & filings" lists what the company itself has put on record with regulators, who inside it traded, the news that names it, and the next date we know of. Filings and releases are first-hand; news is third-party and may be thin for smaller companies. A day of insider filings is one row. Nothing here is a recommendation.

AI Summary

US Stock

ConcernThe company made a net loss of 1.1 billion US dollars in fiscal 2025.

Strengths

No strength stands out for this company on the data on file.

Prices to the 20 Nov 2026 close · Financial year: fiscal 2025

Rule-based from financial data. Not advice.

About the company

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units.

Read moreShow less

QuidelOrtho Corporation provides diagnostic testing solutions. The company operates through Labs, Transfusion Medicine, Point of Care, and Molecular Diagnostics business units. The Labs business unit provides clinical chemistry laboratory instruments and tests that measure target chemicals in bodily fluids for the evaluation of health and the clinical management of patients; immunoassay laboratory instruments and tests, to measure proteins as they act as antigens in the spread of disease, antibodies in the immune response spurred by disease, or markers of proper organ function and health; testing to detect and monitor disease progression across a spectrum of therapeutic areas; and specialized diagnostic solutions. The Transfusion Medicine business unit offers immunohematology instruments and tests used for blood typing to ensure patient-donor compatibility in blood transfusions; and donor screening instruments and tests used for blood and plasma screening for infectious diseases. The Point of Care business unit provides instruments and tests to provide rapid results across a continuum of POC settings. The Molecular Diagnostics business unit offers polymerase chain reaction thermocyclers; amplification systems; and sample-to-result molecular instruments and tests for syndromic infectious disease diagnostics. The company sells its products directly to end users through a direct sales force; and through a network of distributors for professional use in physician offices, hospitals, clinical laboratories, reference laboratories, urgent care clinics, universities, retail clinics, pharmacies, wellness screening centers, blood banks, and donor centers, as well as for individual, non-professional, and over-the-counter use. It operates in North America, Europe, the Middle East, Africa, China, Japan and Asia Pacific, and Latin America. The company was incorporated in 1979 and is headquartered in San Diego, California.

Sector
Healthcare
Shares outstanding
67.9M

Valuation, profitability, growth and solvency at the latest close; hover a label for its meaning.

Valuation

Market cap
$1.0B
P/E
-0.9x
P/B
0.5x
EV / EBITDA
-7.7x
EV / Sales
1.4x
P/S
0.4x
52-week high
$35.38
52-week low
$8.32

Profitability

Operating margin
2.0%
Net margin
-41.5%
EBITDA margin
-17.7%
ROE
-58.9%
ROCE
1.1%
ROA
-19.6%
Asset turnover
0.47

Growth

Revenue
$2.7B
Revenue growth, 1Y
-1.9%
Revenue CAGR, 3Y
-5.8%
Net profit growth, 1Y
-44.8%
Free cash flow
-$83.0M

Solvency

Current ratio
1.50
Debt / Equity
1.48
Debt / Assets
0.49
CFO / Net profit
-0.09
Cash / Market cap
16.3%

Where the revenue went

FY2025 ended in a loss, so the lines are listed rather than drawn as a flow.

LineFY2025
Revenue$2.7B
Cost of revenue$1.5B
Gross profit$1.3B
Operating expenses$1.2B
Research and development$186.2M
Selling, general and administrative$746.3M
Operating income$54.8M
Interest and other-$1.2B
Pretax income-$1.1B
Tax and other$24.1M
Net income-$1.1B

Revenue and net profit

Revenue fell 1.9% in FY2025; net profit is the dashed line.

QuidelOrtho Corporation revenue and net profit by fiscal year
QuidelOrtho Corporation revenue and net profit by fiscal year
DateRevenueNet profit
FY2022$3.3B$548.7M
FY2023$3.0B-$10.1M
FY2024$2.8B-$2.1B
FY2025$2.7B-$1.1B

Cash flows

FY2025: $105.2M from operations, -$83.0M free after investment (dashed).

QuidelOrtho Corporation operating and free cash flow by fiscal year
QuidelOrtho Corporation operating and free cash flow by fiscal year
DateOperating cash flowFree cash flow
FY2022$885.3M$744.4M
FY2023$280.2M$70.9M
FY2024$83.0M-$112.1M
FY2025$105.2M-$83.0M

Growth

Latest fiscal year 2025: each figure with its change over the year before.

Revenue
$2.7B-1.9%1Y
EBITDA
-$482.6M
Net profit
-$1.1B
Cash from operations
$105.2M+26.7%1Y
Free cash flow
-$83.0M
Revenue CAGR, 3Y
-5.8%
YearRevenueEBITDANet profitFCFROERevenue growth 1YNet profit growth 1Y
FY2025$2.7B-$482.6M-$1.1B-$83.0M-58.9%-1.9%-44.8%

Monthly returns

Month-by-month returns of QDEL across the years, with the seasonal pattern.

Balance sheet

What the company owns and owes at the end of FY2025.

LineFY2025
Assets$5.8B
Liabilities$3.8B
Equity$1.9B
Paid-in capital$2.9B
Retained earnings-$996.0M

Market cap against peers

8 peers: same sector, nearest by size.

Peers map

Healthcare companies placed by value, growth and quality; QDEL highlighted.

P/E against peers

QDEL has no positive P/E; the peer median is 19.7x.

Not shown (no positive earnings and no EV / Sales): QuidelOrtho Corporation, Omada Health, Inc., Azenta, Inc., EyePoint, Inc.

Peer comparison

Same-sector peers by market cap, with the median.

CompanyMarket capP/EP/BROEEV/EBITDA
QuidelOrtho CorporationQDELthis company$1.0B-0.9x0.5x-58.9%-7.7x
Omada Health, Inc.OMDA$1.1B-84.7x4.7x-5.6%-181.0x
Xeris Biopharma Holdings, Inc.XERS$1.1B1916.5x77.6x4.0%28.6x
Collegium Pharmaceutical, Inc.COLL$1.1B16.9x3.5x20.8%4.1x
CONMED CorporationCNMD$1.1B22.5x1.0x4.6%10.5x
Azenta, Inc.AZTA$1.1B-18.9x0.6x-3.2%20.8x
The Pennant Group, Inc.PNTG$1.0B35.4x3.1x8.9%24.4x
EyePoint, Inc.EYPT$1.0B-4.4x3.4x-75.8%-4.1x
Artivion, Inc.AORT$1.0B103.7x2.3x2.2%18.9x
Peer median—19.7x3.3x3.1%14.7x

Year-to-date ROI

QDEL since 1 January, against earlier years.

Historical volatility

QDEL's day-to-day swings over 30, 60 and 180 days.

Financial statements

Income statement, balance sheet and cash flow as reported, grouped into plain-language lines.

Consolidated figures in USD, fiscal years, newest first.

Operating margin by fiscal year

QuidelOrtho Corporation operating margin by fiscal year
QuidelOrtho Corporation operating margin by fiscal year
DateOperating margin
FY202230.1%
FY20238.6%
FY20241.6%
FY20252.0%
LineFY2025
Cost of revenueCost Of Revenue$1.5B
Gross profitGross Profit$1.3B
Operating expensesOperating Expense$1.2B
Research and developmentResearch And Development$186.2M
Other operating expensesOther Operating Expenses$97.7M
Depreciation and amortisationDepreciation And Amortization In Income Statement$189.2M
Depreciation, amortisation and depletionDepreciation Amortization Depletion Income Statement$189.2M
Amortization$189.2M
Amortisation of intangiblesAmortization Of Intangibles Income Statement$189.2M
Total expensesTotal Expenses$2.7B
Pretax incomePretax Income-$1.1B

Learn while you research

Academy chapters picked for QuidelOrtho Corporation and the metrics on this page.

  1. 01 Stock Valuation BasicsHow to think about what a fair price for a stock looks like.7 min read
  2. 02 Stock Market RisksSmall caps carry concentrated, idiosyncratic risk, learn to manage it.6 min read
  3. 03 Sector Analysis MattersHealthcare valuation is driven by pipelines and regulation, not just numbers.6 min read
  4. 04 Essential Stock RatiosP/E, P/B, EV/EBITDA, what they mean and when to use each.7 min read
  5. 05 How to Read a Cash-Flow StatementProfit can be manipulated; cash flow rarely lies.7 min read
Browse the full Equiscale Academy →